Article

The Importance of Clinical Trials in Multiple Myeloma

As patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

The list of available treatment options for multiple myeloma has grown in the past decade, However, as patients progress through therapy, it is important that oncologists not disregard the novel agents that are currently being investigated in clinical trials, according to Memorial Sloan Kettering Cancer Center’s Dr. Sham Mailankody.

In an interview with OncLive®, CURE®’s sister publication, Mailankody explained how investigational drugs can play a role in the treatment of patients with myeloma as they advance past the initial lines of treatment.

Transcription:

I think with all these different treatment options, particularly in the relapsed/refractory setting, referring patients when appropriate to clinical trials of these novel treatments — for instance, the CAR-T cells and bispecific antibodies and others that are coming along that are not currently available as standard treatments but might provide significant clinical benefit for patients in the context of clinical trials — would be something else I think people should keep in mind as they see patients through their treatment course.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content